Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

6,930 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Nationwide epidemiological survey of familial myelodysplastic syndromes/acute myeloid leukemia in Japan: a multicenter retrospective study.
Takaoka K, Koya J, Yoshimi A, Toya T, Kobayashi T, Nannya Y, Nakazaki K, Arai S, Ueno H, Usuki K, Yamashita T, Imanishi D, Sato S, Suzuki K, Harada H, Manabe A, Hayashi Y, Miyazaki Y, Kurokawa M. Takaoka K, et al. Among authors: yamashita t. Leuk Lymphoma. 2020 Jul;61(7):1688-1694. doi: 10.1080/10428194.2020.1734595. Epub 2020 Mar 11. Leuk Lymphoma. 2020. PMID: 32157945
A nationwide survey on central nervous system multiple myeloma in Japan: analysis of prognostic and treatment factors that impact survival.
Yamashita T, Takamatsu H, Kawamura K, Sunami K, Hagiwara S, Itagaki M, Takahashi T, Kondo T, Ikeda T, Watakabe-Inamoto K, Handa H, Imaizumi Y, Kuroda J, Murakami J, Nakamura Y, Nakazawa H, Ozaki S, Okura M, Takeuchi M, Nagai H, Hanamura I, Nakao S, Iida S. Yamashita T, et al. Br J Haematol. 2021 Oct;195(2):217-229. doi: 10.1111/bjh.17717. Epub 2021 Jul 28. Br J Haematol. 2021. PMID: 34318926
Outcomes of poor peripheral blood stem cell mobilizers with multiple myeloma at the first mobilization: A multicenter retrospective study in Japan.
Miyamoto-Nagai Y, Mimura N, Tsukada N, Aotsuka N, Ri M, Katsuoka Y, Wakayama T, Suzuki R, Harazaki Y, Matsumoto M, Kumagai K, Miyake T, Ozaki S, Shono K, Tanaka H, Shimura A, Kuroda Y, Sunami K, Suzuki K, Yamashita T, Shimizu K, Murakami H, Abe M, Nakaseko C, Sakaida E. Miyamoto-Nagai Y, et al. Among authors: yamashita t. EJHaem. 2022 Jul 21;3(3):838-848. doi: 10.1002/jha2.534. eCollection 2022 Aug. EJHaem. 2022. PMID: 36051061 Free PMC article.
Clinical Implications of t(11;14) in Patients with Multiple Myeloma Undergoing Autologous Stem Cell Transplantation.
Takamatsu H, Yamashita T, Kurahashi S, Saitoh T, Kondo T, Maeda T, Nakazawa H, Murata M, Narita T, Kuroda J, Hashimoto H, Kawamura K, Miyamoto T, Honda S, Ichinohe T, Atsuta Y, Sunami K. Takamatsu H, et al. Among authors: yamashita t. Biol Blood Marrow Transplant. 2019 Mar;25(3):474-479. doi: 10.1016/j.bbmt.2018.11.003. Epub 2018 Nov 10. Biol Blood Marrow Transplant. 2019. PMID: 30423479 Free article.
Improved survival outcomes and relative youthfulness of multiple myeloma patients with t(4;14) receiving novel agents are associated with poorer performance of the revised international staging system in a real aging society.
Abe Y, Sunami K, Yamashita T, Ueda M, Takamatsu H, Narita K, Kobayashi H, Kitadate A, Takeuchi M, Matsue K. Abe Y, et al. Among authors: yamashita t. Oncotarget. 2019 Jan 15;10(5):595-605. doi: 10.18632/oncotarget.26562. eCollection 2019 Jan 15. Oncotarget. 2019. PMID: 30728910 Free PMC article.
Measurable Residual Disease Assessment Using Next-Generation Flow in Patients With Relapsed and Refractory Multiple Myeloma Treated With a Combination of Carfilzomib, Lenalidomide, and Dexamethasone.
Yoroidaka T, Yamashita T, Murata R, Yoshihara K, Yoshihara S, Ueda M, Nakao S, Matsue K, Takamatsu H. Yoroidaka T, et al. Among authors: yamashita t. Anticancer Res. 2023 Jan;43(1):157-165. doi: 10.21873/anticanres.16145. Anticancer Res. 2023. PMID: 36585165
6,930 results